我院2008-2012年抗肿瘤药的药物利用研究  

Drug Utilization Research of Antineoplastic Drugs in Our Hospital from 2008 to 2012

作　　者：李丹露[1] 庄海英[1] 李希娜[1] 陈希[1] 海鑫 

机构地区：[1]哈尔滨医科大学附属第一医院药学部,哈尔滨150001

出　　处：《中国药房》2014年第34期3191-3196,共6页China Pharmacy

摘　　要：目的:分析我院2008-2012年抗肿瘤药的用药现状及发展趋势。方法:利用我院的医院信息系统,收集我院2008-2012年抗肿瘤药的用药信息,并进行药物利用分析(包括金额排序分析、用药频度分析、日均费用分析、序号比分析等)。结果:我院2008-2012年抗肿瘤药的用药金额呈上升趋势,序号比>1.00的药物平均为11种,占58%;肿瘤科2008-2012年序号比>1.00的药物平均为9种,占58.7%;血液科2008-2012年序号比>1.00的药物平均为11种,占58.3%,总体说明全院抗肿瘤药的用药金额与用药次数同步性较好。结论:我院抗肿瘤药的使用基本合理,但应该更多地选择用药金额与用药次数同步性好的抗肿瘤药。OBJECTIVE： To analyze the situation and development tendency of antineoplastic drugs in our hospital from 2008 to 2012. METHODS： By using HIS, The information of the utilization of antineoplastic drugs in our hospital from 2008 to 2012 were collected and analyzed in respects of consumption sum order, DDDs, DDC and ratio of serial number, etc. RESULTS： From 2008 to 2012, the sum of antineoplastic drugs presented a tendency of increasing and the antineoplastic drugs with serial number ratio 〉 1.00 accounted for 58% （11 kinds）. Meanwhile, the antineoplastic drugs with serial number ratio〉 1.00 accounted for 58.7% in the oncology department （9 kinds） and 58.3% in the hematology department （11 kinds） during 2008-2012. On the whole, the sum and the frequency of the antineoplastic drugs had better synchronization in the hospital. CONCLUSIONS： The utilization of antineoplastic drug is basically reasonable in our hospital, but the antineoplastic drugs with the better synchronization of the sum and the frequency should be used more.

关 键 词：抗肿瘤药 药物利用研究 合理用药 

分 类 号：R969.3[医药卫生—药理学] R197.323[医药卫生—药学]